Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NM283 plus Peg-IFNα-2a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW) |
| Name | Type | Description |
|---|---|---|
| NM283 plus Peg-IFNα-2a | DRUG | 200 mg QD 180 µg QW |
Inclusion Criteria: * Documented clinical history compatible with chronic hepatitis C and compensated liver disease * Has not previously received anti-viral therapy for hepatitis C infection Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient is pregnant or breastf...
NM283 plus Peg-IFNα-2a is used for the treatment of chronic hepatitis C. It is an investigational combination therapy being studied in a Phase 2 clinical trial. The drug is a small molecule developed by Merck & Company, Inc. (MRK) for this infectious disease indication.
NM283 plus Peg-IFNα-2a is developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this combination therapy for chronic hepatitis C, with one completed Phase 2 trial involving 114 participants.
NM283 plus Peg-IFNα-2a is in Phase 2 clinical development. It is an investigational combination therapy for chronic hepatitis C and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
NM283 plus Peg-IFNα-2a was studied in clinical trial NCT00395421, titled "Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin." This Phase 2 trial enrolled 114 participants with chronic hepatitis C in the United States and has been completed.
NM283 plus Peg-IFNα-2a is a combination therapy that includes valopicitabine, also known as NM283, plus pegylated interferon alfa-2a (Peg-IFNα-2a). The clinical trial NCT00395421 evaluates the drug-drug interaction between valopicitabine and ribavirin, indicating that valopicitabine is a component of the combination.